Stock PNAX PANAXIA LABS ISRAEL LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Panaxia Labs Israel Ltd Share Price TEL AVIV STOCK EXCHANGE

Equities

PNAX

IL0011043630

Investment Management & Fund Operators

Financials

Sales 2022 39.42M 10.61M 845M Sales 2023 19.59M 5.27M 420M Capitalization 22.44M 6.04M 481M
Net income 2022 -43M -11.57M -921M Net income 2023 -13M -3.5M -279M EV / Sales 2022 1.63 x
Net Debt 2022 36.12M 9.72M 774M Net Debt 2023 36.1M 9.71M 774M EV / Sales 2023 2.99 x
P/E ratio 2022
-0.65 x
P/E ratio 2023
-1.69 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 61.48%
More Fundamentals * Assessed data

Chart Panaxia Labs Israel Ltd

Dynamic Chart

Latest news about Panaxia Labs Israel Ltd

Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Joseph Herman acquired 3.33% stake in Panaxia Labs Israel Ltd for ILS 1 million. CI
Panaxia Labs Israel Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Panaxia Labs Israel Ltd. and AxioNovo GmbH to Market Cannabis-Based Products in Germany CI
Panaxia Labs Israel Ltd. and Neuraxpharm Receive Regulatory Permit from the German Authorities, for Marketing and Distribution of Medical Cannabis Extracts for Inhalation CI
Panaxia Labs Israel Ltd. Announces Earnings Results for the First Quarter of 2021 CI
Panaxia and Leriva Announces Exclusive Collaborations in Greece CI
More news

Press releases Panaxia Labs Israel Ltd

Panaxia Labs Israel : Unlimited price fluctuation- the shares will open for trading on Wednesday, 1 May 2024 with an "Opening Parameter" of 1 Agora PU
Panaxia Labs Israel : The sector classification of the company will be changed, as of May 02, 2024 from – BIOMED - CANNABIS to FINANCIAL SERVICES - FINANCIAL SERVICES PU
More press releases

Managers and Directors - Panaxia Labs Israel Ltd

Managers TitleAgeSince
Dadi Segal CEO
 Chief Executive Officer 48 30/09/19
Assi Rotbart CHM
 Chairman 49 30/09/19
Ilan Hillel Tamir DFI
 Director of Finance/CFO 66 27/12/22
Members of the board TitleAgeSince
Michal Yageel BRD
 Director/Board Member 54 28/12/21
Tal Yaron Eldar BRD
 Director/Board Member 60 20/07/16
Michal Sapir BRD
 Director/Board Member 66 16/03/22
More insiders

Company Profile

Panaxia Labs Israel Ltd is an Israel-based company that is principally engaged in cannabis industry. The Company provides pharma-grade smokeless cannabis products that provide better delivery systems for patients and physicians when properly assessing safety and dosage. Panaxia pharmaceutical cannabis products are specifically tailored to meet a broad range of needs. It's product portfolio includes: NAXIVA-PANAXOL Advanced kit for preparation of cannabis oil-standardized extract, NAXIVA-PANAXOL Purified extract for inhalation, PANAXIR Medical Cannabis Orodispersible Tablets, PANAXIR SENSE Orange Creamsicle Medical cannabis sublingual drops, PANAXIR CBD Melatonin Tablets, PANAXIR Medical cannabis extracts in ethanol among others.
Sector
Investment Management & Fund Operators
More about the company

Sector Investment Management

1st Jan change Capi.
BLACKSTONE INC. Stock Blackstone Inc.
-6.31% 94.17B
KKR & CO. INC. Stock KKR & Co. Inc.
+22.56% 91.52B
ARES MANAGEMENT CORPORATION Stock Ares Management Corporation
+18.79% 27.7B
LEGAL & GENERAL PLC Stock Legal & General Plc
-1.91% 18.41B
AMUNDI Stock Amundi
+15.91% 15.55B
THE CARLYLE GROUP INC. Stock The Carlyle Group Inc.
+2.85% 15.29B
FRANKLIN RESOURCES, INC. Stock Franklin Resources, Inc.
-19.72% 12.49B
HDFC ASSET MANAGEMENT COMPANY LIMITED Stock HDFC Asset Management Company Limited
+14.61% 9.3B
BLUE OWL CAPITAL INC. Stock Blue Owl Capital Inc.
+25.07% 9.29B
Investment Management
  1. Stock Market
  2. Equities
  3. BARI Stock
  4. PNAX Stock